Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study

28 Jun 2019

Abstract excerpt

Abstract Support from human genetics increases the probability of success in drug development. However, few examples exist of successful genomically-driven drug repositioning. Given that a Mendelian form of severe enterocolitis is due to up-regulation of the interleukin-18 (IL18) signaling pathway, and pharmacologic inhibition of IL18 has been shown to reverse this enterocolitis, we undertook a Mendelian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Celiac Disease Research and Management
Share to Immunodeficiency and Autoimmune Disorders
Share to Inflammatory Bowel Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31253830
DOI: 10.1038/s41598-019-45747-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization studyPMID 31253830Read ↗

Mendelian randomization study for the roles of IL-18 and IL-1 receptor antagonist in the development of inflammatory bowel disease.Semantic proximity Read ↗

Evaluation of causal associations between interleukin-18 levels and immune-mediated inflammatory diseases: a Mendelian randomization studySemantic proximity Read ↗

Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis.Semantic proximity Read ↗

Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of Inflammatory bowel diseaseSemantic proximity Read ↗

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study.Semantic proximity Read ↗

Mendelian randomization reveals predictive, preventive, and personalized insights into inflammatory bowel disease: the role of gut microbiome and circulating inflammatory proteinsSemantic proximity Read ↗

Identification of Novel Drug Target Genes in Inflammatory Bowel Disease through Mendelian Randomization Study and Single-Cell AnalysisSemantic proximity Read ↗

Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization.Semantic proximity Read ↗

Assessing inflammatory protein factors in inflammatory bowel Disease using multivariable mendelian randomization.Semantic proximity Read ↗

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19Semantic proximity Read ↗

Mendelian randomization investigation of the causal association between circulating cytokines and colorectal cancerSemantic proximity Read ↗

A Positive Causal Influence of IL-18 Levels on the Risk of T2DM: A Mendelian Randomization StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.